Valspodar

Valspodar (PSC833) is an experimental cancer treatment and chemosensitizer drug. It is a derivative of ciclosporin D.

Its primary use is that of a P-glycoprotein inhibitor. Previous studies in animal models have found it to be effective at preventing cancer cell resistance to chemotherapeutics, but these findings did not translate to clinical success.